RT Journal Article
SR Electronic
T1 PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.02.20186783
DO 10.1101/2020.09.02.20186783
A1 White, James Robert
A1 Foote, Michael Bonner
A1 Jee, Justin
A1 Argilés, Guillem
A1 Wan, Jonathan C.M.
A1 Diaz, Luis Alberto
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.02.20186783.abstract
AB There is an urgent need to identify therapies to prevent and treat SARS-CoV-2 infection. We performed a statistical evaluation of in vitro gene expression profiles reflecting exposure to 1,835 drugs, and found topoisomerase inhibitors and PI3K/mTOR pathway inhibitors among the strongest candidates for reduced expression of ACE2, a host gene associated with SARS-CoV-2 infection. Retrospective clinical data suggest that patients on these agents may be less likely to test positive for SARS-CoV-2.Competing Interest StatementJRW is the founder and owner of Resphera Biosciences, LLC. JJ holds a patent licensed by MDSeq, Inc. GA has received honoraria for advisory roles from Hoffman La-Roche, Bayer and Servier and honoraria for speaking engagements from Hoffman La-Roche, Bristol Myers Squibb, Bayer and Servier. GA has received travel grants from Hoffman La-Roche, Bayer, Servier, Amgen and Merck and research funds have been awarded to GA from Bayer. GA is an uncompensated advisor for Menarini and Treos Bio, Inc. LAD is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. LAD is a paid consultant to PGDx, 4Paws and Neophore. LAD is an uncompensated consultant for Merck but has received research support for clinical trials from Merck. LAD is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and LAD. LAD also holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore, and his spouse holds equity in Amgen. The terms of these arrangements for LAD are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies.Funding StatementResearch supported by a Stand Up to Cancer Colorectal Cancer Dream Team Translation Cancer Research Grant (SU2C-AACR-DT22-17). Stand up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. M.B.F. is partially supported by a T32 NIH Scholar Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center. Retrospective data was obtained from an IRB-approved study of adult cancer patients tested for SARS-CoV-2 receiving active antineoplastic therapy at Memorial Sloan Kettering Cancer Center (MSKCC) during the COVID-19 epidemic period.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLINCS Phase I data are publicly available through NCBI (GEO accession GSE92742) and the LINCS Data Portal 2.0 (http://lincsportal.ccs.miami.edu/). Procedures on LINCS signature generation and moderated Z-score calculation can be found in the GEO LINCS user guide (v2.1; https://docs.google.com/document/d/1q2gciWRhVCAAnlvF2iRLuJ7whrGP6QjpsCMq1yWz7dU/edit#).Aggregated patient data used in this study is available upon request from the corresponding author (L.A.D.). Requests will be first reviewed for compliance with the ethical and patient privacy regulations of the Memorial Sloan Kettering Cancer Center. http://lincsportal.ccs.miami.edu/ https://docs.google.com/document/d/1q2gciWRhVCAAnlvF2iRLuJ7whrGP6QjpsCMq1yWz7dU/edit https://www.ncbi.nlm.nih.gov/geo/